Here are the editors' top picks for the week ended Jan. 11.
GSK turns to adult respiratory vaccines in bid to replicate Shingrix success
GlaxoSmithKline PLC is looking to develop more vaccines for older adults, including one for smoker's cough and for the respiratory syncytial virus, in a bid to replicate the success of its newly launched Shingrix vaccine.
Competition for Keytruda, Opdivo in China may intensify after Junshi drug launch
Shanghai Junshi Biosciences Co. Ltd.'s melanoma therapy Tuo Yi, priced at 7,200 yuan per vial, is the first approved domestic PD-1 class of check point inhibitors in China.
Wis. governor advances Medicaid expansion, but Republican support still needed
Wisconsin Gov. Tony Evers used his first full day in office to advance his goal of expanding the state's Medicaid program, but the Democrat still has to win over Republicans in the state legislature to make his campaign promise a reality.
US FDA headed for longest shutdown, despite House approval of spending bill
The House adopted a spending bill that would fully open the U.S. Food and Drug Administration, but the Republican Senate leader has no plans to bring the measure up in his chamber, all but assuring the longest shutdown in the agency's history.
Sanders, Dems unveil bills to lower drug costs; House Oversight to probe prices
Sen. Bernie Sanders, I-Vt., and a number of Democratic lawmakers said they were tired of their colleagues on Capitol Hill proposing ideas to lower drug costs, only to see those measures go nowhere.
Of Mice Not Men: Llamas and flu prevention; TB treatment in a spray
Scientists are using antibodies made by llamas in the latest quest to find a treatment to prevent the flu.
M&A activity in Q4'18 targets more pharmaceutical companies
The fourth quarter of 2018 saw a continued M&A appetite for drugmakers as buyers snapped up more pharmaceutical companies than those operating in other healthcare sectors, an analysis of S&P Global Market Intelligence data shows.
House votes to intervene in health lawsuit; DOJ seeks pause during shutdown
Three Republicans joined House Democrats in adopting a resolution to intervene in a lawsuit challenging the constitutionality of the Affordable Care Act — former President Barack Obama's signature legislative achievement.
2 Democratic states, NYC unveil plans to reshape their healthcare systems
While the future of the Affordable Care Act remains uncertain, Washington, California and New York City are all seeking public healthcare plans to extend coverage and services to uninsured residents.
Work requirements, coverage expansion will define Medicaid policy in 2019
Medicaid, the U.S. health insurance program for low-income Americans, will remain in the spotlight in 2019 as some states seek to expand coverage and others impose limits, experts said.
Healthcare IPOs in 2018 outearn 2017's haul despite dip in volume
The year 2018 saw 186 healthcare IPOs globally — slightly fewer than 2017's 190 but earning over $9 billion more than the previous year, according to data compiled by S&P Global Market Intelligence.
J.P. Morgan Healthcare Conference coverage
Intuitive Surgical CEO touts positive 2018 fueled by da Vinci success
Speaking at the 2019 J.P. Morgan Healthcare Conference on Jan. 10, Guthart said procedures for the robotic surgery system da Vinci increased 18% in 2018 compared with the prior year.
Abbott Laboratories CFO says company is focused on organic growth, not M&A
During his presentation at the 2019 J.P. Morgan Healthcare Conference, Abbott Laboratories executive vice president, finance and CFO said the M&A opportunities are not the company's main priority.
Bausch Health plans for 'myopia epidemic'; Biogen leans on pipeline over M&A
CEOs from the world's largest pharmaceutical companies teased investors at the packed J.P. Morgan Healthcare Conference with details of potential future acquisitions, new research areas and "megatrends" that will drive growth in 2019 and beyond.
Medtronic's stock price drops over 6% after CFO projects FY'20 headwinds
Medtronic PLC saw its stock price fall over 6% Jan. 7 after the company's CFO projected a fiscal year 2020 headwind. The projection came shortly after the company's presentation at the 2019 J.P. Morgan Healthcare Conference.
Bristol-Myers CEO: Cash flow, cell therapy made $74B Celgene deal compelling
Celgene Corp.'s cash-generating cancer drug Revlimid and its experimental cell therapies made a compelling case for a takeover of the company, Bristol-Myers Squibb Co. Chairman and CEO Giovanni Caforio told investors at the J.P. Morgan Healthcare Conference.